TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
1 Year Est. Return
+18.15%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Holding
186
Top Buys
| 1 | +$20M | |
| 2 | +$14.2M | |
| 3 | +$14.1M | |
| 4 |
Insulet
PODD
|
+$13.3M |
| 5 |
Baxter International
BAX
|
+$11.2M |
Top Sells
| 1 | +$31.7M | |
| 2 | +$22.5M | |
| 3 | +$22.3M | |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
Sector Composition
| 1 | Healthcare | 96.11% |
| 2 | Real Estate | 2.09% |
| 3 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
176
DELISTED
Merus
MRUS
| – | – |
-69,025
|
|
||
177
Option Care Health
OPCH
$5.02B
| – | – |
-64,975
|
|
||
178
Ultragenyx Pharmaceutical
RARE
$2.22B
| – | – |
-67,065
|
|
||
179
Syndax Pharmaceuticals
SNDX
$1.92B
| – | – |
-117,717
|
|
||
180
Travere Therapeutics
TVTX
$2.64B
| – | – |
-418,520
|
|
||
|
CTLT
181
DELISTED
CATALENT, INC.
CTLT
| – | – |
-49,406
|
|
||
|
VECT
182
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| – | – |
-682,834
|
|
||
|
RXDX
183
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-50,538
|
|
||
|
CSII
184
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-174,859
|
|
||
185
Zai Lab
ZLAB
$2.06B
| – | – |
-34,640
|
|